Valeria Iannone

Ms. Valeria Iannone


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2021 in Tissue Barriers
Verified
Journal Article
Open access
MFMaria Victoria Fernandez-Cantos
Maria Victoria Fernandez-Cantos
DGDiego Garcia-Morena
Diego Garcia-Morena
VIValeria Iannone
Valeria Iannone
Hani El-NezamiHani El-Nezami
Hani El-Nezami
Marjukka KolehmainenMarjukka Kolehmainen
Marjukka Kolehmainen
OKOscar Kuipers
Oscar Kuipers
The Gastrointestinal (GI) tract is composed of four main barriers: microbiological, chemical, physical and immunological. These barriers play important roles in maintaining GI tract homeostasis. In the crosstalk between these barriers, microbiota and related metabolites have been shown to influence GI tract barrier integrity, and alterations of the gut microbiome might lead to an increase in intestinal permeability. As a consequence, translocation of bacteria and their products into the circulatory system increases, reaching proximal and distal tissues, such as the liver. One of the most prevalent chronic liver diseases, Nonalcoholic Fatty Liver Disease (NAFLD), has been associated with an altered gut microbiota and barrier integrity. However, the causal link between them has not been fully elucidated yet. In this review, we aim to highlight relevant bacterial taxa and their related metabolites affecting the GI tract barriers in the context of NAFLD, discussing their implications in gut homeostasis and in disease.

10 April 2025 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
VIValeria Iannone
Valeria Iannone
MVMaija Vaittinen
Maija Vaittinen
CGCarlos Gómez-Gallego
Carlos Gómez-Gallego
Santtu MikkonenSanttu Mikkonen
Santtu Mikkonen
JLJohnson Lok
Johnson Lok
Marjukka KolehmainenMarjukka Kolehmainen
Marjukka Kolehmainen
Background: Visceral adipose tissue (VAT) accumulation in obesity has been implicated as a key factor in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Apart from lifestyle change interventions, there is no effective therapy against MASLD. In this study, the effect of a novel microbial therapy along with dietary change on VAT and VAT-liver crosstalk was evaluated in a MASLD mouse model. Methods: MASLD was induced by feeding eighteen C57BL/6J male mice with the American Lifestyle-Induced Obesity diet for fourteen weeks. Subsequently, during the following seven weeks, all mice were switched to standard diet and the intervention group received single gelatine cubes containing 109 CFU each of aldafermin-expressing Escherichia coli Nissle (EcNA, n = 6); while the control groups received either 109 CFU/gelatine cube of non-modified Escherichia coli Nissle (EcN, n = 6) or gelatin cube with no treatment (CTRL, n = 6). The effect of EcNA on epididymal visceral adipose tissue (eVAT) morphology was evaluated by histology and the gene expression profile in eVAT and liver by RNA-sequencing analysis. Results: After seven weeks of intervention, EcNA, when compared to CTRL group, induced smaller adipocytes (p-value = 0.0217 for diameter, p-value = 0.0386 for area). Gene Set Enrichment Analysis in eVAT showed significant upregulation of fatty acid metabolism (FDR-adjusted p-value = 0.001), oxidative phosphorylation (FDR-adjusted p-value < 2.2e-16), peroxisome (FDR-adjusted p-value = 0.0185), and thermogenesis (FDR-adjusted p-value = 0.0199) pathways when EcNA was compared to EcN group. In addition, the impact of EcNA in eVAT-liver gene expression crosstalk was underlined by the upregulation of Bcl6 and Cnst expression in both tissues when EcNA was compared to CTRL and EcN groups. Conclusions: These results support the beneficial effects of EcNA, along with dietary change intervention, in obesity-associated MASLD. This microbial therapy could potentially boost the improvements induced by dietary change in eVAT metabolism and its crosstalk with the liver.

8 March 2024 in Proceedings
Verified
Conference Paper
Open access
PDF file
JLJohnson Lok
Johnson Lok
VIValeria Iannone
Valeria Iannone
CGCarlos Gómez-Gallego
Carlos Gómez-Gallego
RVRuben Vazquez-Uribe
Ruben Vazquez-Uribe
MSMorten Otto Alexander Sommer
Morten Otto Alexander Sommer
HEHani El-Nezami
Hani El-Nezami
Background and objectives: Endocrine dysregulation and intestinal microbiota unbalance are commonly associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to investigate the effectiveness of engineered probiotic Escherichia coli Nissle (EcN) 1917 expressing various hormones (IGF1, GLP-1, FGF19, Adiponectin) downregulated in MASLD as a potential therapeutic. Methods: 41 C57BL/6J mice underwent 14 weeks of a high-fat diet intervention for MASLD development. The mice were then separated into seven groups and underwent 7 weeks of probiotic intervention while under the control diet. The mice were grouped as follows: (1) without probiotic; (2) EcN without hormone expression; (3–6) EcN expressing IGF1, GLP-1, FGF19, and Adiponectin, respectively; and (7) liraglutide treatment. Liver fat was measured using MRI and the Oil-Red-O staining of liver histological samples. 16s rRNA sequencing was used to investigate the bacterial composition in mice cecum. Results: Mice receiving EcN expressing IGF1, GLP-1, and FGF19 were effective at reducing liver fat accumulation. Microbiota compositions were different between groups, and the microbial communities of mice receiving EcN expressing IGF1 and FGF19 had higher observed richness. Mice receiving EcN-IGF1 had lower abundance of sulfate-reducing bacteria (Desulfobacterota) associated with gut inflammation and higher abundance of butyrate-producing bacteria (Roseburia sp.) and Lactobacillus reuteri. Mice receiving EcN-FGF19 had lower abundance of bacteria associated with intestinal inflammation (Coriobacteriia) and higher abundance of SCFA-producing bacteria (Roseburia sp. and Blautia sp.) and plasma propionate levels. Discussion: EcN expressing IGF1 and FGF19 have the potential to reduce liver fat accumulation and restore microbial equilibrium. This may be a combined effect of hormones and EcN, as a probiotic, thereby improving gut endocrine and immune functions.